- Home
- OWLS vs FLGT Comparison
OWLS vs FLGT Comparison
Compare OWLS & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OWLS
- FLGT
- Stock Information
- Founded
- OWLS 2010
- FLGT 2011
- Country
- OWLS Taiwan
- FLGT United States
- Employees
- OWLS N/A
- FLGT N/A
- Industry
- OWLS Computer Software: Prepackaged Software
- FLGT Medical Specialities
- Sector
- OWLS Technology
- FLGT Health Care
- Exchange
- OWLS Nasdaq
- FLGT Nasdaq
- Market Cap
- OWLS 795.4M
- FLGT 697.3M
- IPO Year
- OWLS N/A
- FLGT 2016
- Fundamental
- Price
- OWLS $9.00
- FLGT $26.36
- Analyst Decision
- OWLS
- FLGT Buy
- Analyst Count
- OWLS 0
- FLGT 3
- Target Price
- OWLS N/A
- FLGT $25.33
- AVG Volume (30 Days)
- OWLS 331.1K
- FLGT 242.6K
- Earning Date
- OWLS 01-01-0001
- FLGT 11-07-2025
- Dividend Yield
- OWLS N/A
- FLGT N/A
- EPS Growth
- OWLS N/A
- FLGT N/A
- EPS
- OWLS N/A
- FLGT N/A
- Revenue
- OWLS $7,569,630.00
- FLGT $315,549,000.00
- Revenue This Year
- OWLS N/A
- FLGT $15.19
- Revenue Next Year
- OWLS N/A
- FLGT $10.58
- P/E Ratio
- OWLS N/A
- FLGT N/A
- Revenue Growth
- OWLS 18.29
- FLGT 13.61
- 52 Week Low
- OWLS $7.48
- FLGT $14.57
- 52 Week High
- OWLS $90.00
- FLGT $27.36
- Technical
- Relative Strength Index (RSI)
- OWLS N/A
- FLGT 72.55
- Support Level
- OWLS N/A
- FLGT $22.12
- Resistance Level
- OWLS N/A
- FLGT $23.15
- Average True Range (ATR)
- OWLS 0.00
- FLGT 0.89
- MACD
- OWLS 0.00
- FLGT 0.11
- Stochastic Oscillator
- OWLS 0.00
- FLGT 80.19
About OWLS OBOOK Holdings Inc. Class A Common Shares
OBOOK Holdings Inc is focused on using blockchain technology to provide inventive solutions to customers in various sectors, including financial services, hospitality, and e-commerce. Through its e-commerce, hospitality and payments offerings, it is committed to serving businesses and individuals whose commercial activities involve cross-border transactions.
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.